Thiabendazole
CAS 148-79-8
Thiabendazole (CAS 148-79-8) is a Phase 4 pharmaceutical compound with 8 bioactivity targets and 0 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Clinical Development Phase
Highest clinical development phase rendered from the matched compound identifier rows.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Bioactivity & Target Interactions
Target-level activity records with assay counts, activity type, and measured value where present.
| Target | Activity | Value | Assays | Organism |
|---|---|---|---|---|
| - | GI50 | 94277.69603448277 nM | 60 | - |
| - | Potency | 27792.26923076923 nM | 49 | - |
| - | AC50 | 25652.299189189187 nM | 37 | - |
| - | EC50 | 15282.92857142857 nM | 14 | - |
| - | EC50 | 5.412727272727273 ug.mL-1 | 11 | - |
| - | IC50 | 16573.057777777776 nM | 8 | - |
| - | MIC | 677.0833333333334 ug.mL-1 | 3 | - |
| - | Kd | 60000 nM | 1 | - |
| - | Ki | 400 nM | 1 | - |
| - | MIC | 3000000 nM | 1 | - |
| Peptidyl-prolyl cis-trans isomerase FKBP1A Enzyme |
Kd | 4.22 | - | Homo sapiens |
| Cytochrome P450 1A2 Enzyme |
IC50 | 6.097 | - | Homo sapiens |
| Succinate dehydrogenase [ubiquinone] flavoprotein subunit, mitochondrial Enzyme |
- | - | - | Caenorhabditis elegans |
| Methionine aminopeptidase 2 Enzyme |
IC50 | 4.35 | - | Homo sapiens |
| Reverse transcriptase/RNaseH Enzyme |
IC50 | 4.84 | - | Human immunodeficiency virus 1 |
| Methionine aminopeptidase Enzyme |
IC50 | 6.33 | - | Escherichia coli (strain K12) |
| Methionine aminopeptidase 1 Enzyme |
EC50 | 5.47 | - | Homo sapiens |
| Tubulin Structural |
INHIBITOR | - | - | Echinococcus granulosus |
| Tubulin Structural |
INHIBITOR | - | - | Ascaris suum |
Side Effects
SIDER side-effect terms mapped to the drug or same-CAS compound identity.
| Side Effect | Drug Name | MedDRA Type | Concept ID |
|---|---|---|---|
| Abdominal pain | thiabendazole | LLT | C0000737 |
| Abdominal pain | thiabendazole | PT | C0000737 |
| Anaphylactic shock | thiabendazole | LLT | C0002792 |
| Anaphylactic shock | thiabendazole | PT | C0002792 |
| Angioedema | thiabendazole | LLT | C0002994 |
| Angioedema | thiabendazole | PT | C0002994 |
| Anorexia | thiabendazole | LLT | C0003123 |
| Asthenia | thiabendazole | LLT | C0004093 |
| Asthenia | thiabendazole | PT | C0004093 |
| Asthenia | thiabendazole | PT | C0004093 |
| Chills | thiabendazole | LLT | C0085593 |
| Chills | thiabendazole | PT | C0085593 |
| Cholestasis | thiabendazole | LLT | C0008370 |
| Cholestasis | thiabendazole | PT | C0008370 |
| Confusional state | thiabendazole | LLT | C0009676 |
| Confusional state | thiabendazole | PT | C0009676 |
| Conjunctival hyperaemia | thiabendazole | LLT | C1761613 |
| Conjunctival hyperaemia | thiabendazole | PT | C1761613 |
| Convulsion | thiabendazole | LLT | C0036572 |
| Convulsion | thiabendazole | PT | C0036572 |
| Coordination abnormal | thiabendazole | LLT | C0520966 |
| Coordination abnormal | thiabendazole | PT | C0520966 |
| Crystalluria | thiabendazole | LLT | C0151579 |
| Crystalluria | thiabendazole | PT | C0151579 |
| Decreased appetite | thiabendazole | PT | C0232462 |
| Dermatitis | thiabendazole | PT | C0011603 |
| Diarrhoea | thiabendazole | LLT | C0011991 |
| Diarrhoea | thiabendazole | PT | C0011991 |
| Dizziness | thiabendazole | LLT | C0012833 |
| Dizziness | thiabendazole | PT | C0012833 |
| Drowsiness | thiabendazole | LLT | C0013144 |
| Dyspepsia | thiabendazole | PT | C0013395 |
| Enuresis | thiabendazole | LLT | C0014394 |
| Enuresis | thiabendazole | PT | C0014394 |
| Epigastric distress | thiabendazole | LLT | C0221490 |
| Erythema multiforme | thiabendazole | LLT | C0014742 |
| Erythema multiforme | thiabendazole | PT | C0014742 |
| Erythema multiforme | thiabendazole | PT | C0014742 |
| Fatigue | thiabendazole | LLT | C0015672 |
| Fatigue | thiabendazole | PT | C0015672 |
| Feeling abnormal | thiabendazole | PT | C1443060 |
| Flushing | thiabendazole | LLT | C0016382 |
| Flushing | thiabendazole | PT | C0016382 |
| Gastrointestinal pain | thiabendazole | PT | C0687713 |
| Haematuria | thiabendazole | LLT | C0018965 |
| Haematuria | thiabendazole | PT | C0018965 |
| Headache | thiabendazole | LLT | C0018681 |
| Headache | thiabendazole | PT | C0018681 |
| Hepatic failure | thiabendazole | LLT | C0085605 |
| Hepatic failure | thiabendazole | PT | C0085605 |
| Hepatocellular injury | thiabendazole | LLT | C0151763 |
| Hepatocellular injury | thiabendazole | PT | C0151763 |
| Hyperglycaemia | thiabendazole | LLT | C0020456 |
| Hyperglycaemia | thiabendazole | PT | C0020456 |
| Hypersensitivity | thiabendazole | LLT | C0020517 |
| Hypersensitivity | thiabendazole | PT | C0020517 |
| Hypoaesthesia | thiabendazole | PT | C0020580 |
| Hypotension | thiabendazole | LLT | C0020649 |
| Hypotension | thiabendazole | PT | C0020649 |
| Jaundice | thiabendazole | LLT | C0022346 |
| Jaundice | thiabendazole | PT | C0022346 |
| Leukopenia | thiabendazole | LLT | C0023530 |
| Leukopenia | thiabendazole | PT | C0023530 |
| Liver injury | thiabendazole | PT | C0160390 |
| Lymphadenopathy | thiabendazole | LLT | C0497156 |
| Lymphadenopathy | thiabendazole | PT | C0497156 |
| Nausea | thiabendazole | LLT | C0027497 |
| Nausea | thiabendazole | PT | C0027497 |
| Numbness | thiabendazole | LLT | C0028643 |
| Pruritus | thiabendazole | LLT | C0033774 |
| Pruritus | thiabendazole | PT | C0033774 |
| Rash | thiabendazole | LLT | C0015230 |
| Rash | thiabendazole | PT | C0015230 |
| Sensory loss | thiabendazole | PT | C0278134 |
| Sjogren's syndrome | thiabendazole | PT | C1527336 |
| Somnolence | thiabendazole | PT | C2830004 |
| Stevens-Johnson syndrome | thiabendazole | LLT | C0038325 |
| Stevens-Johnson syndrome | thiabendazole | PT | C0038325 |
| Syndrome sicca | thiabendazole | LLT | C0086981 |
| Tinnitus | thiabendazole | LLT | C0040264 |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Thiabendazole used for in pharmaceutical contexts?
Thiabendazole (CAS 148-79-8) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Thiabendazole?
Thiabendazole has SIDER side-effect terms including Abdominal pain, Anaphylactic shock, Angioedema, Anorexia, Asthenia; no DrugCentral/FAERS adverse-event association rows are rendered for this page. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Thiabendazole also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for Thiabendazole with EU status "prohibited".
What clinical phase is Thiabendazole in?
Thiabendazole is rendered with ChEMBL max phase 4 (approved).
What bioactivity targets are documented for Thiabendazole?
Thiabendazole has 19 bioactivity rows in this page query. Rendered target entries include Peptidyl-prolyl cis-trans isomerase FKBP1A, Cytochrome P450 1A2, Succinate dehydrogenase [ubiquinone] flavoprotein subunit, mitochondrial, Methionine aminopeptidase 2, Reverse transcriptase/RNaseH.